Other, Publications Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model
ALG-055009, Publications Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics
ALG-055009, Publications Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH
Preclinical, Publications ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo
Publication, Publications Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Publication, Publications Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry
Preclinical, Publications ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model
Preclinical, Publications Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity
ALG-000184, Publications Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of Multiple Doses of ALG-000184 in Healthy Volunteers (HV) and Subjects with Chronic Hepatitis B (CHB)
Publication, Publications ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model